July 21, 2026/
Angioedema with darolutamide, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome with gemcitabine, neurodevelopmental disorders with paternal valproate exposure, fixed drug eruption with iodinated X-ray...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Angioedema with darolutamide, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome with gemcitabine, neurodevelopmental disorders with paternal valproate exposure, fixed drug eruption with iodinated X-ray...
Insulin Syringe Safety, Drug-Drug Interactions with Valproic Acid and Methotrexate, and Denosumab-Induced Mineral Metabolism Disturbances
The Egyptian Drug Authority (EDA) published its third version of the Good Pharmacovigilance Practice (GVP) guideline in 2026, representing a significant evolution in Egypt's pharmacovigilance regulatory...
